BIOLIFE SOLUTIONS INCBLFS決算レポート
Nasdaq · ヘルスケア · 電子医療及び電気療法装置
BIOLIFE SOLUTIONS INCは、細胞・遺伝子治療、バイオ医薬品、再生医療分野向けの特殊な生体保存製品とコールドチェーン管理ソリューションを開発・製造・販売しています。凍結保存培地、自動解凍システム、温度監視ツールなどを提供し、世界中のバイオテクノロジー企業、研究機関、臨床検査室を支援しています。
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| NOS. OF ABOVE PERSONS | 19.50% | 8.7M | — | 2023-10-24 |
| BlackRock, Inc. | 12.30% | 5.4M | — | 2024-01-23 |
| OF ABOVE PERSONS | 7.00% | 3.2M | — | 2024-11-08 |
| The Vanguard Group | 5.71% | 2.6M | — | 2024-02-13 |
| Integrated Core Strategies | 5.30% | 2.4M | ▼ -0.20pp | 2024-01-24 |
| THE GOLDMAN SACHS GROUP, INC. | 0.40% | 161.5K | ▼ -5.10pp | 2024-11-01 |
インサイダー取引
Net 90d: −$2.06M · buys $0 / sells $2.06M期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-03-23 | Foster Karen A. | Chief Quality and Operations | Sell (open market) | 2.6K | $19.17 | $49.4K |
| 2026-03-09 | Foster Karen A. | Chief Quality and Operations | Sell (open market) | 500 | $20.00 | $10.0K |
| 2026-03-05 | Foster Karen A. | Chief Quality and Operations | Sell (open market) | 96.9K | $20.15 | $1.95M |
| 2026-03-03 | Mathew Aby J. | EVP & Chief Scientific Officer | Sell (open market) | 529 | $20.74 | $11.0K |
| 2026-03-03 | Foster Karen A. | Chief Quality and Operations | Sell (open market) | 418 | $20.74 | $8.7K |
| 2026-03-03 | Sarah Aebersold | Chief Human Resources Officer | Sell (open market) | 219 | $20.74 | $4.5K |
| 2026-03-03 | Todd Berard | Chief Marketing Officer | Sell (open market) | 353 | $20.74 | $7.3K |
| 2026-03-03 | Troy Wichterman | Chief Financial Officer | Sell (open market) | 588 | $20.74 | $12.2K |
| 2026-03-03 | Sean Werner | Chief Technology Officer | Sell (open market) | 111 | $20.74 | $2.3K |
| 2026-02-24 | Todd Berard | Chief Marketing Officer | Grant | 20.1K | — | — |
1–10 of 27
1 / 3 ページ